Clinical Trial Update: Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)

View source ↗

Summary

This is a regulatory post-marketing surveillance study in Korea for Leqvio (inclisiran) in patients with primary hypercholesterolemia or mixed dyslipidemia that…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Mixed Dyslipidemia

Drugs mentioned

• LEQVIO (inclisiran)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Hypercholesterolemia or Mixed Dyslipidemia | Status: RECRUITING